Il Messaggiere - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
RBGPF 0% 77.27 $
NGG 0.45% 70.68 $
CMSC 0.66% 24.3 $
RIO 0.37% 62.1 $
SCS -0.96% 16.72 $
RYCEF 1.48% 14.87 $
RELX -4.56% 45.13 $
GSK -0.69% 40.5 $
BCE -0.25% 24.14 $
VOD -1.8% 11.65 $
BCC 0.68% 85.87 $
CMSD -0.12% 24.34 $
JRI 1.71% 14.02 $
BTI 0% 56.26 $
BP 1.93% 34.76 $
AZN -0.51% 80.81 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

A.Bruno--IM